Digital technologies to support self-management of asthma: early-use assessment

1 Purpose of this document

NICE's assessment of digital technologies to support self-management of asthma recommends that more evidence is generated while Asthmahub, Asthmahub for parents, Digital Health Passport, Luscii, myAsthma, RDMP (Respiratory Disease Management Platform) and Smart Asthma are being used in the NHS. Two technologies (AsthmaTuner and JOE Digital Therapeutic) will be included in the recommendation when they are available in the NHS. These 2 technologies are included in this plan to support their evidence generation.

This plan outlines the evidence gaps and what data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. Evidence generated through other study approaches will also be considered. For assessing comparative treatment effects, well-conducted randomised controlled trials are the preferred source of evidence.

The companies are responsible for ensuring that data collection and analysis takes place.

NICE will withdraw the guidance if the companies do not meet the conditions in section 4 on monitoring.

After the end of the evidence generation period (3 years), the companies should submit the evidence to NICE in a format that can be used for decision making. NICE will review all the evidence and assess whether the technologies can be routinely adopted in the NHS.